Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) EBIAT (2020 - 2025)

Vivos Therapeutics has reported EBIAT over the past 6 years, most recently at -$7.0 million for Q4 2025.

  • Quarterly EBIAT fell 149.16% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.2 million through Dec 2025, down 91.55% year-over-year, with the annual reading at -$21.2 million for FY2025, 91.26% down from the prior year.
  • EBIAT was -$7.0 million for Q4 2025 at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • Over five years, EBIAT peaked at -$1.7 million in Q1 2023 and troughed at -$7.4 million in Q4 2021.
  • The 5-year median for EBIAT is -$4.6 million (2023), against an average of -$4.5 million.
  • Year-over-year, EBIAT plummeted 200.74% in 2021 and then soared 68.05% in 2023.
  • A 5-year view of EBIAT shows it stood at -$7.4 million in 2021, then increased by 18.23% to -$6.0 million in 2022, then increased by 29.15% to -$4.3 million in 2023, then surged by 34.84% to -$2.8 million in 2024, then plummeted by 149.16% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBIAT are -$7.0 million (Q4 2025), -$5.4 million (Q3 2025), and -$5.0 million (Q2 2025).